JPMorgan’s Names Top Biotech Stocks
- Investing.com
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.2x | −0.2x | −0.2x | |
PEG Ratio | −4.22 | −0.13 | 0.00 | |
Price / Book | 3.9x | 1.0x | 2.6x | |
Price / LTM Sales | - | 3.3x | 2.6x | |
Upside (Analyst Target) | 59.8% | 77.2% | 77.0% | |
Fair Value Upside | Unlock | 38.2% | 13.7% | Unlock |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.